Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PBF 680

Drug Profile

PBF 680

Alternative Names: PBF-680

Latest Information Update: 11 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Palobiofarma
  • Developer Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Palobiofarma
  • Class Antiasthmatics
  • Mechanism of Action Adenosine A1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 07 Sep 2024 Efficacy and adverse event data from the phase II ADENOASMA trial in Asthma presented at the 34th Annual Congress of the European Respiratory Society (ERS-2024)
  • 28 Jun 2022 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in Spain (PO, Capsule)
  • 20 Dec 2021 Phase-II clinical trials in Chronic obstructive pulmonary disease in Spain (PO) (NCT05262218) (EudraCT2021-001732-25)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top